Fycompa
Epilepsy
Humanis Saglık Anonim SirketiPhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 73/ 100
Competitive context
76 Active assets in the Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax SK Life Science, Inc. | Phase 4 | BBB |
Lacosamide Second Affiliated Hospital of Guangzhou Medical University | Phase 4 | BBB |
Carbamazepine Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
Topamax Université de Sherbrooke | Phase 4 | BBB |
Keppra Beijing Tiantan Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Fycompa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →